Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.

What was studied

A double-blind phase 3 trial compared survodutide with placebo for weight and glycemic outcomes.

Who / model studied

752 adults with type 2 diabetes and BMI of at least 27.

Studied dose & schedule

Subcutaneous survodutide 3.6 mg or 6.0 mg once weekly, versus placebo, over 76 weeks.

What the study found

The three groups at 76 weeks

Survodutide3.6 mg weekly

250 participants

Mean weight change−8.2%95% CI: −9.2% to −7.2%

• Lost at least 5% of body weight57.6%
• HbA1c reductionPercentage points0.9
• Gastrointestinal events72.8%

Survodutide6.0 mg weekly

251 participants

Mean weight change−9.8%95% CI: −10.8% to −8.8%

• Lost at least 5% of body weight64.5%
• HbA1c reductionPercentage points0.8
• Gastrointestinal events77.7%

PlaceboWeekly injection

251 participants

Mean weight change−3.9%95% CI: −4.9% to −2.9%

• Lost at least 5% of body weight35.1%
• HbA1c reductionPercentage points0.2
• Gastrointestinal events38.6%

How to read these numbers: Weight changes use treatment-regimen estimates, including participants who discontinued or interrupted treatment or used other antiobesity therapies. Baseline HbA1c was 7.4%. GI events were generally transient and mild to moderate.

Limitations & context

Treatment-regimen estimates include discontinuation or interruption. Placebo comparison cannot establish superiority to other incretins. Cardiovascular benefit and the glucagon pathway contribution were not established by these reported outcomes. Sponsor: Boehringer Ingelheim. Abstract assessment only.

Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary